SCI Pharmtech Inc (4119) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of SCI Pharmtech Inc TWD 18.02, price TWD 56.70, upside -68.2%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch SCI Pharmtech Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals.
Show more
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, and valproic acid; and develops benserazide, CBN, and CBDv. It also provides intermediate products, such as diethyl isobutyl malonate, benzhydrylamine, 1-Benzhydrylazetidin-3-ol, azetidin-3-ol hydrogenchloride, 1-(2-hydroxyphenyl)-3-phenylpropan-1-one, ritalinic acid, d-ritalinic acid HCl, pyrogallol aldehyde, menthadienol, 5-pentylbenzene-1,3-diol olivetol, methyl 2,4-dihydroxy-6-pentylbenzoate, ethyl 2,4-dihydroxy-6-pentylbenzoate ethyl olivetolate, divarinol, lisdexamfetamine intermediate, UDP-GIcNAz, and UDP-GaINAz. In addition, the company offers customized production services. It operates in Italy, Spain, the Netherlands, Belgium, the United States, Japan, Germany, Taiwan, Switzerland, and internationally. SCI Pharmtech, Inc. was incorporated in 1987 and is based in Taoyuan City, Taiwan.
Stock analysis
SCI Pharmtech Inc (4119) currently trades at 56.70 TWD, while our model-based Fair Value estimate is 18.02 TWD, implying the stock looks roughly 214.7% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 30.24 TWD per share, and 0 of the 16 models we run sit above the 56.70 TWD price.
Bear case: the Earnings-Based group reads lowest at 6.88 TWD, and 16 of the 16 models stay below the price. Evidence for this calculation is high.
Scenario range: 11.46 TWD (bear) to 19.85 TWD (bull), the price of 56.70 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
SCI Pharmtech Inc reported revenue of 1.3B TWD in FY2025 versus 864M TWD in FY2021, a compound +11.7%/yr. Reported net income was 107M TWD in FY2025, compounding +17.8%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 6.8B TWD (≈ $214M) · P/E ratio 63.0 · P/S ratio 5.03 · EPS (TTM) 0.9000 TWD · Dividend yield 1.3% · Net margin 8.0% · Return on equity 1.8% · Return on assets (EBIT) 3.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 6% below its 52-week high and 40% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −68%, 4119 screens richer than that median.
Fair Value models
Bear 11.46 TWDFair Value 18.02 TWDBull 19.85 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.1101 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.0%
Start year 2020 (pandemic). Over 10 years: −2.9% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−19.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−21.2%
Dividend (yield on the price)1.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−23% vs −13%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 12%
Start year 2020 (pandemic)
⚠ Revenue per share shrinking 2.1%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score38 · Bottom 25%
Fair Value upside−68% · Bottom 25%
Profitability
Return on equity (TTM)2% · Below median
Return on assets1% · Below median
Net margin (TTM)7% · Above median
Operating margin (TTM)9% · Below median
Growth and dividend
Revenue growth4% · Above median
Dividend yield (TTM)1.3% · Below median
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)63.0× · Priciest 25%
P/B1.26× · Cheaper than median
P/S (TTM)5.00× · Priciest 25%
EV/EBITDA17.4× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)22· sector 20
PAST (return on equity)7· sector 27
HEALTH (low debt)98· sector 96
DIVIDEND (yield)26· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is SCI Pharmtech Inc (4119) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 18.02 TWD versus a price of 56.70 TWD, about −68% upside (overvalued).
What is the fair value of 4119?
Our model-based fair value for SCI Pharmtech Inc is 18.02 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 56.70 TWD.
What is the quality score of 4119?
SCI Pharmtech Inc has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SCI Pharmtech Inc (4119)?
Our model-based price target is the fair value of 18.02 TWD (as of Sep 24, 2026) from 16 valuation models. Cautious scenario 11.46 TWD, optimistic scenario 19.85 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the SCI Pharmtech Inc stock forecast for 2026?
Our models put fair value at 18.02 TWD, about −68% upside versus a price of 56.70 TWD (overvalued). Cautious scenario 11.46 TWD, optimistic scenario 19.85 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of SCI Pharmtech Inc (4119)?
SCI Pharmtech Inc reported trailing-twelve-month revenue of about 1.4B TWD (latest available figure, as of Sep 24, 2026).
Does SCI Pharmtech Inc pay a dividend?
SCI Pharmtech Inc currently shows a dividend yield of about 1.32% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of SCI Pharmtech Inc (4119)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SCI Pharmtech Inc it is 18.02 TWD per share (as of Sep 24, 2026), against a price of 56.70 TWD. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is SCI Pharmtech Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4119 trades above its calculated fair value: price 56.70 TWD, fair value 18.02 TWD, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4119?
No. The price is what the market pays today (56.70 TWD); the fair value is what the company's own numbers justify (18.02 TWD). For SCI Pharmtech Inc the two are 38.68 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is SCI Pharmtech Inc worth?
The market values SCI Pharmtech Inc at about 6.8B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 56.70 TWD; our models calculate a fair value of 18.02 TWD per share.
What do the bullish and bearish scenarios say about 4119?
Our models span a range for SCI Pharmtech Inc: cautious scenario 11.46 TWD, base 18.02 TWD, optimistic 19.85 TWD per share (as of Sep 24, 2026, price 56.70 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4119?
SCI Pharmtech Inc trades at a price-to-earnings ratio of 63.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 18.02 TWD is built from several models across several years. Other multiples: P/B 1.3, P/S 5.0, EV/EBITDA 17.4.
How solid is the balance sheet of SCI Pharmtech Inc (4119)?
Balance-sheet figures for SCI Pharmtech Inc (as of Sep 24, 2026): return on equity 1.8%, debt of 0.05 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is 4119 from its 52-week high?
SCI Pharmtech Inc trades at 56.70 TWD, about 6% below its 52-week high of 60.20 TWD and 40% above the low of 40.40 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 18.02 TWD is for.
Which stocks are comparable to SCI Pharmtech Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SCI Pharmtech Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 56.70 TWD, calculated fair value 18.02 TWD (−68%), Quality Score 38/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4119 calculated?
We run SCI Pharmtech Inc through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 18.02 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. SCI Pharmtech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SCI Pharmtech Inc (4119)?
The closing price on Sep 24, 2026 was 56.70 TWD. Our model-based fair value is 18.02 TWD, about −68% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SCI Pharmtech Inc right now?
The price sits above even our optimistic bull case (19.85 TWD). The favourable scenario is already priced in. Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts.
Where does the earnings growth of SCI Pharmtech Inc (4119) come from?
Earnings per share at SCI Pharmtech Inc grew −2.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share −3.5 %, EBIT margin −6.9 %, tax rate +0.3 %, residual (interest, one-offs) +8.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of SCI Pharmtech Inc
How large is the market capitalisation of SCI Pharmtech Inc (4119)?
The market capitalisation of SCI Pharmtech Inc is 6.8B TWD (≈ $214M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SCI Pharmtech Inc (4119)?
The price-to-sales ratio of SCI Pharmtech Inc is 5.03 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SCI Pharmtech Inc (4119)?
Earnings per share at SCI Pharmtech Inc are 0.9000 TWD (price ÷ EPS = P/E 63.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SCI Pharmtech Inc (4119)?
The dividend yield of SCI Pharmtech Inc is 1.3% (payout 83.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SCI Pharmtech Inc (4119)?
The net margin of SCI Pharmtech Inc is 8.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SCI Pharmtech Inc (4119)?
The return on equity (ROE) of SCI Pharmtech Inc is 1.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SCI Pharmtech Inc (4119)?
On an EBIT basis the return on assets of SCI Pharmtech Inc is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SCI Pharmtech Inc (4119)?
The operating margin of SCI Pharmtech Inc is 8.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SCI Pharmtech Inc (4119)?
Revenue at SCI Pharmtech Inc is growing +4.3% versus a year earlier (3y avg +14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SCI Pharmtech Inc (4119)?
Earnings per share at SCI Pharmtech Inc are growing −35.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does SCI Pharmtech Inc (4119) generate?
The free cash flow of SCI Pharmtech Inc is −390M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SCI Pharmtech Inc (4119) carry?
The net debt of SCI Pharmtech Inc is 927M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SCI Pharmtech Inc in the live analysis
One click puts SCI Pharmtech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
